Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Author(s):
Wieske, L.; Stalman, E.W.; Dam, P.J.K. van; Kummer, L.Y.; Steenhuis, M.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.; Kooi, A. van der; Raaphorst, J.; Löwenberg, M.; Takkenberg, B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horváth, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Keijzer, S.; Keijser, J.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Rispens, T.; Eftimov, F.; T2B Immunity SARS CoV 2 Study Grp
Published
2023
Publication type
Article / Letter to editor
Covid-19VaccinationAutoimmune DiseasesTumor Necrosis Factor Inhibitors
Date issued
2023-01-31
Language
English
Publisher
BMJ Publishing Group
Is part of
Annals of the Rheumatic Diseases (2023), Vol. 82, no. 6, p. 883-885
hdl
1887/3677643
doi
10.1136/ard-2022-223464
URL
https://ard.bmj.com/content/82/6/883